Why the study?
Clinical trial results regarding the effect of statins on blood lipid profiles have been inconsistent across different types of cardiovascular diseases.
Does statin therapy improve blood lipid profiles (total cholesterol, LDL-C, TG, HDL-C) in patients with cardiovascular diseases?
Does statin therapy improve blood lipid profiles (total cholesterol, LDL-C, TG, HDL-C) in patients with cardiovascular diseases?
Statin therapy significantly improves the lipid profile by lowering LDL-C, total cholesterol, and triglycerides, and raising HDL-C in patients with various cardiovascular diseases.
Reinforces statin use for lipid management across CVD types; confirms efficacy despite prior trial inconsistencies.
BACKGROUND: Statins are the main lipid-lowering drugs and are used in the prevention of cardiovascular diseases (CVDs). Since the results have been, to some extent, inconsistent in the clinical trials concerning different types of CVDs, a systematic review and meta-analysis was performed to prove the effect of statins on decreasing elevated levels of total cholesterol, triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) in patients with CVDs. METHODS: Literature search was performed on major electronic databases (MEDLINE/ PubMed, Scopus, and ISI Web of Science) from inception up to July 2021 to find randomized controlled trials (RCTs) evaluating the effect of different statins on different types of CVDs. The effect size was determined using weighted mean difference (WMD) and corresponding 95% confidence interval (CI). RESULTS: Statin therapy significantly decreased levels of total cholesterol (WMD = -33.37 mg/dl, 95% CI: -45.98 to -20.76, P<0.001), LDL-C (WMD = -29.42 mg/dl, 95% CI: -36.81 to -22.03, P<0.001), and TG (WMD = -15.19 mg/dl, 95% CI = -26.41 to -3.97, P<0.001), and increased levels of HDL-C (WMD = 1.55 mg/dl, 95% CI: 0.20, to 2.90, P=0.02) in patients with different CVDs. CONCLUSION: Statin therapy was found effective in lowering levels of total cholesterol, LDL-C, and TG, and increasing levels of HDL-C in patients with different CVDs.
No takes yet. Share an insight, caveat, or question.
Aslani et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: